2. Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom (ABC2), Lissabon, 09.11.2013 – ABC2-Konsensus: Bewertung durch eine deutsche Expertengruppe

Zusammenfassung

Vom 7. bis 9. November 2013 fand in Lissabon die zweite internationale Konsensuskonferenz ABC2 (Advanced Breast Cancer Second Consensus) zu Diagnostik und Behandlung des fortgeschrittenen Mammakarzinoms statt. Der inhaltliche Schwerpunkt lag auf dem inoperablen lokal fortgeschrittenen Mammakarzinom. Diagnostik und Therapie des metastasierten Mammakarzinoms waren bereits vor zwei Jahren anlässlich des ABC1-Konsensus diskutiert worden und wurden im Rahmen des diesjährigen ABC2-Konsensus nur in einzelnen Fragestellungen aktualisiert. Wie schon vor zwei Jahren hat eine Arbeitsgruppe deutscher Brustkrebsexperten die Abstimmungsergebnisse der ABC-Panelisten unter besonderer Berücksichtigung der deutschen Leitlinien zu Diagnostik und Therapie des Mammakarzinoms (AGO-Empfehlungen, S3-Leitlinie) [1] [2] mit Blick auf den Therapiealltag in Deutschland kommentiert. Ziel sowohl des ABC-Konsensus als auch der deutschen Kommentierung ist es, eine evidenzbasierte Grundlage für die Therapieentscheidung zu schaffen.

Abstract

The Advanced Breast Cancer Second International Consensus Conference (ABC2) on diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, from November 7th to 9th, 2013. The focus of the Conference was inoperable, locally advanced breast cancer. Diagnosis and treatment of metastatic breast cancer had already been discussed two years ago at the ABC1 Consensus and were updated only regarding special issues as part of this year’s ABC2 Consensus. Like two years ago, a working group of German breast cancer experts commented on the voting results of the ABC panelists, with special consideration of the German guidelines for diagnosis and treatment of breast cancer (AGO [German Gynecological Oncology Working Group] recommendations, S3 Guideline) [1] [2] in order to adapt them for daily clinical practice in Germany. The goal of both the ABC Consensus and the German comments is to facilitate evidence-based therapy decisions.

Schlüsselwörter

lokal fortgeschrittenes Mammakarzinom - LABC - metastasiertes Mammakarzinom

Key words

locally advanced breast cancer - LABC - metastatic breast cancer

• Literatur

• 1 www.awmf.org
• 2 www.ago-online.de
• 3 Cardoso F et al. 1^st International consensus guidelines for advanced breast cancer (ABC1). The Breast 2012; 21 (03) 242-252
• 4 Buzdar A et al. ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. Proc ASCO JCO 2013; 502
• 5 Baselga J et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. NEJM 2012; 366: 520-529
• 6 Gelmon KA et al. An open-label, randomized, phase III trial comparing taxane-based chemotherapy with Lapatinib or Trastuzumab as first-line therapy for women with HER2-positive metastatic breast cancer. Proc ASCO 2012; JCO 2012, 30 (suppl): LBA671.
• 7 Pivot X et al. CEREBEL (EGF 111438): An open randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ MBC treated with lapatinib plus capecitabine versus trastuzumab plus capecitabine. Ann Oncol 2012; 23 (Suppl. 09)
• 8 Baselga J et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. NEJM 2012; 366: 109-119
• 9 Swain S et al. Confirmatory Overall Survival Analysis of CLEOPATRA: A Randomized Double-Blind Placebo-Controlled Phase III Study with Pertuzumab, Trastuzumab and Docetaxel in Patients with HER2-Positive First-Line MBC. Proc SABCS 2012; P5-18-26
• 10 Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. NEJM 2012; 367 (19) 1783-1791
• 11 Wildiers H et al. T-DM1 for HER2-positive MBC: Primary Results From TH3RESA, a Phase 3 Study of T-DM1 vs. Treatment of Physician’s Choice. Proc ECC 2013; LBA 15.
• 12 Harbeck N, Wuerstlein R. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer. Evidence and clinical considerations. Drugs 2013; 73: 1665-1680